Therapeutic Area

Epilepsy

Therapeutic area intelligence for Epilepsy with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 1

Companies

BIOCODEX SA →

Assets

DIACOMIT →

Eisai →

Recent signals(3)

ClinicalJuly 5, 2026

Study on Social Feedback's Impact on Intracranial EEG in Epilepsy Patients

A clinical trial is assessing how social feedback influences neural recordings in epilepsy patients during surgery.

RegulatoryJuly 4, 2026

FDA Accepts Supplement for DIACOMIT (Stiripentol) by BIOCODEX SA

The FDA has accepted a supplemental application for DIACOMIT (Stiripentol) submitted by BIOCODEX SA.

ClinicalJuly 2, 2026

Eisai's Fycompa Injection Safety Study for Epilepsy Underway

Eisai is conducting a study to evaluate the safety of Fycompa injection in patients with partial-onset seizures and primary generalized tonic-clonic seizures.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Epilepsy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.